Companies: 10,795·Total market cap: $144.5T

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc.

AQSTNASDAQHealthcare● Active

$3.90

$-0.04(-0.89%)

Market Cap$386799347

P/E Ratio—

52W High$7.55

52W Low$2.93

Avg Volume1.6M

Open$4.00

Beta1.45

Net Income Financials Revenue

Aquestive Therapeutics, Inc. (AQST) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

AQST · net income · updated Jun 8, 2026

Core profitability metrics

AQST · net income · margin · TTM · CAGR

Net income was −$83.8M for FY2025 (fiscal year ending 2025-12-31), down 89.8% year-over-year. Net profit margin was -188.1%.

FY2025 Net Income−$83.8M▼ -89.8% YoY

Trailing 12M (TTM)−$68.9Mtrailing 4 quarters sum

Net Profit Margin-188.1%−$83.8M ÷ $44.5M

YoY Change-89.8%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · AQST net income history · AQST profit margin

Annual net income data

AQST · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$83.8M▼ 89.8%-188.1%$44.5M

FY2024Loss−$44.1M▼ 460.8%-76.7%$57.6M

FY2023Loss−$7.9M▲ +85.5%-15.6%$50.6M

FY2022Loss−$54.4M▲ +22.9%-114.1%$47.7M

FY2021Loss−$70.5M▼ 26.5%-138.8%$50.8M

Net income vs peers (Healthcare)

AQST vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Aquestive Therapeutics, Inc.YOU

AQST

−$83.8M-89.8%-188.1%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Aquestive Therapeutics, Inc. (AQST) reported net income of −$83.8M for FY2025 (fiscal year ending 2025-12-31), down 89.8% year-over-year. The net profit margin was -188.1% — meaning the company kept $-1.88 of every dollar of revenue as profit.

Aquestive Therapeutics, Inc. has not yet achieved annual profitability based on available data (10 fiscal years). The company has reported net losses across all available periods.

Aquestive Therapeutics, Inc.'s net profit margin was -188.1% for FY2025, based on the latest annual results.

Investors sometimes search for "Aquestive Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from AQST net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

AQST net income · 4 questions

Aquestive Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $83.8M for FY2025.

is AQST profitabledoes AQST make a profitAQST profitabilityAQST profitable company

▸ Source: FMP /income-statement · GAAP · Aquestive Therapeutics, Inc. · Aquestive Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026